MD-BOEHRINGER-INGELHEIM
16.3.2021 14:02:08 CET | Business Wire | Press release
Boehringer Ingelheim and the Lieber Institute for Brain Development (LIBD) today announced a joint research and licensing collaboration focused on the development of novel centrally acting COMT (catechol-O-methyltransferase) inhibitors for the potential treatment of cognitive deficits in a spectrum of neuropsychiatric disorders, including schizophrenia. Aligning with a circuitry-based approach to precision psychiatry, the collaboration will leverage Boehringer Ingelheim’s deep experience in central nervous system (CNS) drug discovery and development alongside Lieber’s expertise in centrally acting COMT inhibitors. Ultimately, the partnership will focus on advancing novel COMT inhibitor candidates into the clinic.
“Psychiatric disorders including cognitive impairment in schizophrenia have historically been difficult indications to treat and continue to remain areas of high unmet need. This collaboration with the Lieber Institute further expands our innovative neuropsychiatric research program, a key focus area at Boehringer Ingelheim, with a first-in-class mechanism that may have the potential to address these symptoms,” said Dr. Hugh Marston, Ph.D., Head of Department CNS Diseases Research at Boehringer Ingelheim. “By combining our expertise, we hope to make significant steps forward to finding solutions for patients for which there currently is no treatment.”
COMT, a dopamine metabolizing enzyme, is key to the modulation of dopamine in the prefrontal cortex and hippocampus of the brain. Adequate function of dopamine signaling is critical for a number of cognitive and behavioral processes that are impaired in a variety of neuropsychiatric and neurological disorders such as schizophrenia. While peripherally acting COMT inhibitors are currently used as an adjunctive therapy in the treatment of neurological conditions, including Parkinson’s disease, this new collaboration is investigating centrally acting COMT inhibitors in neuropsychiatric disorders.
Recent studies from the Lieber Institute suggest an important role of centrally acting COMT inhibitors in the potential symptomatic treatment of various neurological and neuropsychiatric disorders. The potential of centrally acting COMT inhibitors has not yet been evaluated in the clinic due to the unavailability of such compounds. In partnering with the Lieber Institute, Boehringer Ingelheim has in-licensed preclinical pipeline candidates, representing a first-in-class approach for targets in neuropsychiatric disorders.
“The Lieber Institute has a long-standing effort exploring centrally acting COMT inhibitors as part of its mission to understand the genetic and molecular mechanisms of schizophrenia and related brain disorders,” said Daniel R. Weinberger, M.D., LIBD CEO & Director. “We are excited to embark on this partnership with Boehringer Ingelheim to identify potential therapeutic candidates and advance them to clinical development in order to help improve the lives of those affected by this serious mental health condition.”
Financial details of the collaboration were not disclosed.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/collaboration-libd
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005641/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIKE, Inc. Unveils the Next Generation of Innovation Across Performance Sports and Sportswear16.11.2026 15:08:00 CET | Press release
From the next evolution of Nike Air to new Nike Mind and Nike Free footwear, Nike is solving distinct athlete needs — and creating platforms that can bring those breakthroughs to more athletes.New innovations and platforms span running, training, basketball, football and outdoor sports, reflecting Nike's focus on delivering best-in-class performance to athletes across disciplines.Nike is bringing performance innovation into everyday style, reinventing the classics athletes love while introducing new silhouettes, including Project Ride and Nike Morpho X.Much of what Nike is showing arrives over the coming year, with some innovations following later. Watch for more details in the months to come. NIKE, Inc. (NYSE: NKE) is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. This press release features multimedia. View the full release here: https://www.businesswire.com
2027 Cocktail Trends Put a Fresh Spin on Classics, Flavor and the Night Out16.11.2026 13:00:00 CET | Press release
The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience The five emerging movements poised to shape cocktail culture in 2027 were unveiled today in the eighth annual Bacardi Cocktail Trends Report published by Bacardi Limited, the world’s largest privately held international spirits company. Created in collaboration with strategic foresight consultancy The Future Laboratory (TFL), the report combines global consumer research, bartender insights, and industry perspectives to explore how the cocktail experience is evolving. The report also reveals the top cocktails Legal Drinking Age (LDA) consumers plan to order at bars and venues worldwide throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116061749/en/ The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience in 2027. “F
Cordica Medical Launches PTFE Etched Liners for Interventional Catheter Designs16.11.2026 13:00:00 CET | Press release
32 webstore sizes ship in 48 hours, with custom sizes from 0.010" to 0.400" ID built in 2–3 weeks Cordica Medical (Cordica), a medical device contract development and manufacturing organization (CDMO), today launched its PTFE Etched Liner portfolio: lubricious ID, bond-ready etched OD PTFE liners for interventional catheter designs, from cardiovascular to neurovascular and more. Standard sizes are available now on the Cordica webstore and ship in 48 hours. Custom sizes are built in 2–3 weeks. The launch coincides with the first day of COMPAMED 2026 in Düsseldorf, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116876181/en/ Pictured: Cordica’s PTFE Etched Liner. Each liner has a low-friction PTFE inner diameter designed to facilitate device and guidewire passage with a chemically etched outer diameter surface that is designed to enhance bonding to the catheter jacket. The liners are designed to be drawn down over
Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 10:00:00 CET | Press release
Plural’s largest raise to date: almost four times its €260m inaugural fund in 2022, and double its €500m second fund in 2024 All former founders and operators, Plural’s partners back founders early to build generational companies that compete globally from Europe Plural’s companies have raised over €3bn in follow-on capital in the last twelve months alone as European tech accelerates Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe
SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 09:36:00 CET | Press release
Initiative in Malawi, Burundi, Zambia and Zimbabwe will leverage SES satellite solutions to extend digital learning opportunities to 20,000-30,000 students and teachers. SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the futu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
